Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced it has launched a two-gram vial of gemcitabine hydrochloride for injection. The oncology medication is a generic version of Eli Lilly's Gemzar®, which posted 2009 U.S. sales of nearly $750 million for the full range of standard presentations. Hospira's gemcitabine is approved by the U.S. Food and Drug Administration (FDA) for treatment of a variety of cancers... 
More...
More...